CN110300803B - 提高细胞基因组中同源定向修复(hdr)效率的方法 - Google Patents

提高细胞基因组中同源定向修复(hdr)效率的方法 Download PDF

Info

Publication number
CN110300803B
CN110300803B CN201780086730.XA CN201780086730A CN110300803B CN 110300803 B CN110300803 B CN 110300803B CN 201780086730 A CN201780086730 A CN 201780086730A CN 110300803 B CN110300803 B CN 110300803B
Authority
CN
China
Prior art keywords
hdr
cell
nuclease
sequence
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780086730.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN110300803A (zh
Inventor
J·N·费德
郭齐
G·A·敏泰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61006349&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN110300803(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Priority to CN202410548057.9A priority Critical patent/CN118460529A/zh
Publication of CN110300803A publication Critical patent/CN110300803A/zh
Application granted granted Critical
Publication of CN110300803B publication Critical patent/CN110300803B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Developmental Biology & Embryology (AREA)
  • Transplantation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201780086730.XA 2016-12-20 2017-12-20 提高细胞基因组中同源定向修复(hdr)效率的方法 Active CN110300803B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410548057.9A CN118460529A (zh) 2016-12-20 2017-12-20 提高细胞基因组中同源定向修复(hdr)效率的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662437042P 2016-12-20 2016-12-20
US62/437,042 2016-12-20
PCT/US2017/067569 WO2018119060A1 (en) 2016-12-20 2017-12-20 Methods for increasing the efficiency of homology directed repair (hdr) in the cellular genome

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410548057.9A Division CN118460529A (zh) 2016-12-20 2017-12-20 提高细胞基因组中同源定向修复(hdr)效率的方法

Publications (2)

Publication Number Publication Date
CN110300803A CN110300803A (zh) 2019-10-01
CN110300803B true CN110300803B (zh) 2024-05-14

Family

ID=61006349

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780086730.XA Active CN110300803B (zh) 2016-12-20 2017-12-20 提高细胞基因组中同源定向修复(hdr)效率的方法
CN202410548057.9A Pending CN118460529A (zh) 2016-12-20 2017-12-20 提高细胞基因组中同源定向修复(hdr)效率的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410548057.9A Pending CN118460529A (zh) 2016-12-20 2017-12-20 提高细胞基因组中同源定向修复(hdr)效率的方法

Country Status (7)

Country Link
US (1) US20230193321A1 (enExample)
EP (2) EP3559230B1 (enExample)
JP (3) JP2020510443A (enExample)
KR (2) KR20190095412A (enExample)
CN (2) CN110300803B (enExample)
ES (1) ES2962711T3 (enExample)
WO (1) WO2018119060A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015330699B2 (en) 2014-10-10 2021-12-02 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
WO2016073990A2 (en) 2014-11-07 2016-05-12 Editas Medicine, Inc. Methods for improving crispr/cas-mediated genome-editing
EP3353296B1 (en) 2015-09-24 2020-11-04 Editas Medicine, Inc. Use of exonucleases to improve crispr/cas-mediated genome editing
US11597924B2 (en) 2016-03-25 2023-03-07 Editas Medicine, Inc. Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
WO2017180694A1 (en) 2016-04-13 2017-10-19 Editas Medicine, Inc. Cas9 fusion molecules gene editing systems, and methods of use thereof
EP3559230B1 (en) 2016-12-20 2023-09-06 Bristol-Myers Squibb Company Methods for increasing the efficiency of homology directed repair (hdr) in the cellular genome
WO2019014564A1 (en) 2017-07-14 2019-01-17 Editas Medicine, Inc. SYSTEMS AND METHODS OF TARGETED INTEGRATION AND GENOME EDITING AND DETECTION THEREOF WITH INTEGRATED PRIMING SITES
EP3692063A1 (en) * 2017-10-03 2020-08-12 Juno Therapeutics, Inc. Hpv-specific binding molecules
KR20210031482A (ko) * 2018-07-13 2021-03-19 알렐 바이오테크놀로지 앤 파마슈티칼스, 인크. 고-특이성의 게놈 편집을 달성하는 방법
AU2020301025A1 (en) 2019-07-03 2022-01-20 Integrated Dna Technologies, Inc. Identification, characterization, and quantitation of CRISPR-introduced double-stranded DNA break repairs
EP4048803A4 (en) * 2019-10-24 2024-11-13 Integrated Dna Technologies, Inc. MODIFIED DOUBLE-STRANDED DONOR TEMPLATES
CN111549052A (zh) * 2020-05-07 2020-08-18 西南大学 一种真核生物CRISPR/Cas全基因组编辑载体文库及构建方法
JPWO2021251493A1 (enExample) * 2020-06-12 2021-12-16
CN111944847A (zh) * 2020-08-28 2020-11-17 西北农林科技大学 一套等位基因高效替换系统及其建立方法
CN113416730B (zh) * 2021-07-07 2023-04-04 中国医学科学院血液病医院(中国医学科学院血液学研究所) 一种降低细胞因基因编辑产生的大片段删除突变的方法
GB202117455D0 (en) * 2021-12-02 2022-01-19 Academisch Ziekenhuis Leiden Method of editing nucleic acid

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103168101A (zh) * 2010-07-23 2013-06-19 西格马-奥尔德里奇有限责任公司 使用靶向核酸内切酶和单链核酸的基因组编辑
WO2016154579A2 (en) * 2015-03-26 2016-09-29 Editas Medicine, Inc. Crispr/cas-mediated gene conversion
WO2016182959A1 (en) * 2015-05-11 2016-11-17 Editas Medicine, Inc. Optimized crispr/cas9 systems and methods for gene editing in stem cells

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4774085A (en) 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
AU7979491A (en) 1990-05-03 1991-11-27 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
CA2186118C (en) 1994-03-23 2010-10-19 Richard W. Hanson Compacted nucleic acids and their delivery to cells
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US7013219B2 (en) 1999-01-12 2006-03-14 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US8772008B2 (en) * 2009-05-18 2014-07-08 Sangamo Biosciences, Inc. Methods and compositions for increasing nuclease activity
EP4019635A1 (en) 2015-03-25 2022-06-29 Editas Medicine, Inc. Crispr/cas-related methods, compositions and components
KR102888521B1 (ko) 2015-04-06 2025-11-19 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 Crispr/cas-매개 유전자 조절을 위한 화학적으로 변형된 가이드 rna
US10179918B2 (en) 2015-05-07 2019-01-15 Sangamo Therapeutics, Inc. Methods and compositions for increasing transgene activity
CN105734032A (zh) * 2016-03-25 2016-07-06 扬州大学 一种山羊blg基因定点敲除修饰系统及应用
EP3559230B1 (en) 2016-12-20 2023-09-06 Bristol-Myers Squibb Company Methods for increasing the efficiency of homology directed repair (hdr) in the cellular genome

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103168101A (zh) * 2010-07-23 2013-06-19 西格马-奥尔德里奇有限责任公司 使用靶向核酸内切酶和单链核酸的基因组编辑
WO2016154579A2 (en) * 2015-03-26 2016-09-29 Editas Medicine, Inc. Crispr/cas-mediated gene conversion
WO2016182959A1 (en) * 2015-05-11 2016-11-17 Editas Medicine, Inc. Optimized crispr/cas9 systems and methods for gene editing in stem cells

Also Published As

Publication number Publication date
WO2018119060A1 (en) 2018-06-28
US20230193321A1 (en) 2023-06-22
EP4286523A2 (en) 2023-12-06
KR20190095412A (ko) 2019-08-14
JP2020510443A (ja) 2020-04-09
CN110300803A (zh) 2019-10-01
JP2024009934A (ja) 2024-01-23
CN118460529A (zh) 2024-08-09
EP3559230B1 (en) 2023-09-06
JP2026012785A (ja) 2026-01-27
KR20230162134A (ko) 2023-11-28
ES2962711T3 (es) 2024-03-20
EP4286523A3 (en) 2024-03-20
EP3559230A1 (en) 2019-10-30

Similar Documents

Publication Publication Date Title
EP3559230B1 (en) Methods for increasing the efficiency of homology directed repair (hdr) in the cellular genome
US20260043050A1 (en) Genome Engineering
EP3074515B1 (en) Somatic haploid human cell line
EP3472321A2 (en) Crispr-cas system, materials and methods
JP2017536811A (ja) 多能性細胞の樹立又は維持のための方法及び組成物
US11459586B2 (en) Methods for increasing efficiency of nuclease-mediated gene editing in stem cells
US20260132427A1 (en) Methods for increasing the efficiency of homology directed repair (hdr) in the cellular genome
Chang A Programable CRISPR System to Methylate and Demethylate N6-Methlyadenosine on Specific Transcripts in Mammalian Cells
NZ754904A (en) Genome engineering
NZ754904B2 (en) Genome engineering
NZ754903B2 (en) Genome engineering

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment

Free format text: NEW EXPIRY DATE: 20380918

TG01 Patent term adjustment